Format

Send to:

Choose Destination

Links from GEO DataSets

See comment in PubMed Commons below
Nat Med. 2012 Nov;18(11):1673-81. doi: 10.1038/nm.2934. Epub 2012 Sep 9.

Lymph node T cell responses predict the efficacy of live attenuated SIV vaccines.

Author information

  • 1Vaccine and Gene Therapy Institute, Oregon Health and Science University, Beaverton, OR, USA.

Abstract

Live attenuated simian immunodeficiency virus (SIV) vaccines (LAVs) remain the most efficacious of all vaccines in nonhuman primate models of HIV and AIDS, yet the basis of their robust protection remains poorly understood. Here we show that the degree of LAV-mediated protection against intravenous wild-type SIVmac239 challenge strongly correlates with the magnitude and function of SIV-specific, effector-differentiated T cells in the lymph node but not with the responses of such T cells in the blood or with other cellular, humoral and innate immune parameters. We found that maintenance of protective T cell responses is associated with persistent LAV replication in the lymph node, which occurs almost exclusively in follicular helper T cells. Thus, effective LAVs maintain lymphoid tissue-based, effector-differentiated, SIV-specific T cells that intercept and suppress early wild-type SIV amplification and, if present in sufficient frequencies, can completely control and perhaps clear infection, an observation that provides a rationale for the development of safe, persistent vectors that can elicit and maintain such responses.

PMID:
22961108
[PubMed - indexed for MEDLINE]
PMCID:
PMC3493820
Free PMC Article
PubMed Commons home

PubMed Commons

0 comments
How to join PubMed Commons

    Supplemental Content

    Full text links

    Icon for Nature Publishing Group Icon for PubMed Central
    Loading ...
    Write to the Help Desk